Loss-of-function mutations in the α3 isoform of the sodium pump are responsible for Rapid Onset Dystonia-Parkinsonism (RDP). A pharmacologic model of RDP replicates the most salient features of RDP, and implicates both the cerebellum and basal ganglia in the disorder; dystonia is associated with aberrant cerebellar output, and the parkinsonism-like features are attributable to the basal ganglia. The pharmacologic agent used to generate the model, ouabain, is selective for sodium pumps. However, close to the infusion sites in vivo it likely affects all sodium pump isoforms. Therefore, it remains to be established whether selective loss of α3-containing sodium pumps replicates the pharmacologic model. Moreover, while the pharmacologic model suggested that aberrant firing of Purkinje cells was the main cause of abnormal cerebellar output, it did not allow the scrutiny of this hypothesis. To address these questions RNA interference using small hairpin RNAs (shRNAs) delivered via adeno-associated viruses (AAV) was used to specifically knockdown α3-containing sodium pumps in different regions of the adult mouse brain. Knockdown of the α3-containing sodium pumps mimicked both the behavioral and electrophysiological changes seen in the pharmacologic model of RDP, recapitulating key aspects of the human disorder. Further, we found that knockdown of the α3 isoform altered the intrinsic pacemaking of Purkinje cells, but not the neurons of the deep cerebellar nuclei. Therefore, acute knockdown of proteins associated with inherited dystonias may be a good strategy for developing phenotypic genetic mouse models where traditional transgenic models have failed to produce symptomatic mice.
Introduction
Dystonia is thought to affect as many as 250,000 people in the United States alone (Stacy, 2006) . Although dystonia is both common and devastating its etiology remains poorly understood, in part because of the absence of good animal models of the disorder. The majority of dystonias are idiopathic and many are thought to have a genetic component (Phukan et al., 2011; Balint and Bhatia, 2014) . Over the last 20 years more than 30 genes have been identified which are associated with dystonia (Phukan et al., 2011; Balint and Bhatia, 2014; Moghimi et al., 2014) . In many of the cases that have been closely scrutinized the dystonic syndrome is thought to be associated with loss of function of the associated gene (De Carvalho et al., 2004; Goodchild et al., 2005; Esapa et al., 2007; Fuchs et al., 2013) . Unfortunately, to date the majority of transgenic models made to replicate mutations of these causative genes in the mouse have not generated dystonic animals (Richter and Richter, 2014), making examination of the neural and neuronal circuitry which contributes to dystonia challenging.
Rapid-Onset Dystonia Parkinsonism (RDP) is an inherited dystonia caused by loss of function mutations in the α3 isoform of the Na + /K + -ATPase pump (sodium pump) (De Carvalho et al., 2004) ; a protein whose function is widely known and well-studied (Sweadner, 1989; Lingrel, 1992) . Since this discovery, two different genetic animal models of α3 dysfunction have been reported. The first was a knockout of the α3 isoform. Unfortunately, mice with a homozygous knockout died prematurely and could not be studied while heterozygotes exhibited no overt motor phenotype (Moseley et al., 2007; DeAndrade et al., 2010) . In the second model, the gene coding for the α3 isoform has an inactivating point mutation within it. Mice homozygous for this mutation also exhibit early lethality whereas heterozygotes survive and exhibit seizures and ataxia but no clear dystonia (Clapcote et al., 2009) . The failure of these transgenic models in replicating RDP has been attributed to developmental compensatory mechanisms in mice that may be different from those present in humans (Calderon et al., 2011; Fremont and Khodakhah, 2012; Fremont et al., 2014) .
In 2011, a model of RDP was generated which took advantage of the fact that the loss-of-function mutations associated with sodium pumps in RDP could be acutely mimicked by pharmacologically blocking the function of the sodium pumps (Calderon et al., 2011) . In this model Neurobiology of Disease 82 (2015) 200-212 
